Last $5.85 USD
Change Today -0.07 / -1.18%
Volume 11.9K
CFRXU On Other Exchanges
As of 8:10 PM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

contrafect corp (CFRXU) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/29/14 - $7.87
52 Week Low
08/1/14 - $5.24
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CONTRAFECT CORP (CFRXU)

Related News

No related news articles were found.

contrafect corp (CFRXU) Related Businessweek News

No Related Businessweek News Found

contrafect corp (CFRXU) Details

ContraFect Corporation operates as a biotechnology company that focuses on development and commercialization of protein and antibody products for life-threatening, drug-resistant infectious diseases, and particularly those used in hospital-based settings. The company’s product candidates are CF-301 and CF-302, the bacteriophage lysins for the treatment of staph aureus infections; and CF-404, a cocktail of monoclonal antibodies for the treatment of life-threatening seasonal and pandemic varieties of influenza. The company was founded in 2008 and is headquartered in Yonkers, New York.

16 Employees
Last Reported Date: 07/25/14
Founded in 2008

contrafect corp (CFRXU) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $566.8K
Chief Medical Officer
Total Annual Compensation: $441.2K
Chief Scientific Officer
Total Annual Compensation: $374.2K
Compensation as of Fiscal Year 2013.

contrafect corp (CFRXU) Key Developments

ContraFect Corporation Announces Management Changes

ContraFect Corporation announced that it has confirmed the appointment of Ms. Julia P. Gregory as Chief Executive Officer and Director. In addition the board of directors appointed Mr. David N. Low Jr., Michael J. Otto, Ph.D. and Dr. Roger J. Pomerantz M.D., F.A.C.P. to the board, and announced that Sir Richard Sykes, FRS, has resigned from the board. Ms. Gregory served as ContraFect's Executive Vice President and Chief Financial Officer from July 2012 to November 2013, and had functioned as the interim Chief Executive Officer since November 2013. Mr. Low currently serves as a Senior Advisor at Lazard, since 2002 he has been a member of Lazard's Life Sciences Group as a Managing Director. Dr. Otto served as Chief Scientific Officer of Pharmasset from October 1999 until February 2012. Previously, Pomerantz served as Senior Vice President and Global Franchise Head of Infectious Diseases at Merck, in charge of all anti-viral, anti-bacterial and anti-fungal agents, including global strategy.

ContraFect Corporation Auditor Raises 'Going Concern' Doubt

ContraFect Corporation filed its S-1 on Apr 18, 2014 for the period ending Dec 31, 2013. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

ContraFect Corporation Announces Executive Changes

ContraFect Corporation announced that Ms. Julia P. Gregory was appointed interim Chief Executive Officer, succeeding Dr. Robert Nowinski, the founder of the company, who has departed for medical reasons. Ms. Gregory joins Dr. Sol Barer, Chairman of ContraFect Corporation, in a newly formed office of The Chief Executive. Ms. Gregory had been the Company's Executive Vice President and Chief Financial Officer since July 2012. Prior to joining ContraFect, Ms. Gregory was President and Chief Executive Officer of Five Prime Therapeutics Inc.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CFRXU:US $5.85 USD -0.07

CFRXU Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CFRXU.
View Industry Companies

Industry Analysis


Industry Average

Valuation CFRXU Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CONTRAFECT CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at